A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
Despite a recent increase in FDA new drug approvals, leading pharmaceutical companies continue to face R&D productivity challenges. This highlights the need to better understand the context of their R&D concepts and related R&D outputs. Consequently, we conducted a systematic assessment of the impact of R&D expenditures, R&D intensities, mergers & acquisitions (M&A) deals and licensing agreements on new drug approvals of leading pharmaceutical companies between 2012 and 2021. Our analysis provides key insights into differentiating R&D factors: whereas R&D expenditures and the number of M&A deals correlate with the number of new drug approvals, our analysis shows no correlation with R&D intensity or the number of licensing agreements.
Authors
- Markus Hinder (ORCID: https://orcid.org/0000-0003-2293-8342)
- Dominik Hartl
- Alexander Schuhmacher (ORCID: https://orcid.org/0000-0001-7884-5757)
- Oliver Gassmann (ORCID: https://orcid.org/0000-0002-0448-1564)
- Kyrylo Grinchenko
Institutions
- Novartis (Switzerland) (CH)
- University of Basel (CH)
- University of St.Gallen (CH)
- Technische Hochschule Ingolstadt (DE)
- Novartis Foundation (CH)
Publication Details
- Journal
- Drug Discovery Today
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.drudis.2025.104306
- Citations
- 3
- Primary Topic
- Intellectual Property and Patents
- Type
- article
- Field-Weighted Citation Impact
- 8.28